Narcolepsy

Neurology·MeSH: Narcolepsy

Prevalence

30.0 / 100K

30 drugs in development·14 companies·8 clinical trials

Drug Pipeline by Phase

Approved(8)

Drug	Company
dextroamp saccharate	ELITE PHARMACEUTICALS INC /NV/ (ELTP)
LUMRYZ	Alkermes plc. (ALKS)
pitolisant	Impax Laboratories, LLC (IPXL)
pitolisant	Viatris Inc (VTRS)
sodium oxybate	Nascent Biotech Inc. (NBIO)
Sunosi	Axsome Therapeutics, Inc. (AXSM)
WAKIX	Harmony Biosciences Holdings, Inc. (HRMY)
xyrem	Jazz Pharmaceuticals plc (JAZZ)

Phase 3(9)

Drug	Company
ALKS 2680	Alkermes plc. (ALKS)
kp1077	ZEVRA THERAPEUTICS, INC. (ZVRA)
LUMRYZ	AVADEL PHARMACEUTICALS PLC (AVDL)
pitolisant HD	Harmony Biosciences Holdings, Inc. (HRMY)
tak-360	Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK)
tak-360	TAKEDA PHARMACEUTICAL CO LTD (TKPHF)
tak-861	TAKEDA PHARMACEUTICAL CO LTD (TKPHF)
tak-861	Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK)
tak-861	Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK)

Phase 2(2)

Drug	Company
AXS-12	Axsome Therapeutics, Inc. (AXSM)
ORX750	Centessa Pharmaceuticals plc (CNTA)

Phase 1(4)

Drug	Company
BP1.15205	Harmony Biosciences Holdings, Inc. (HRMY)
bupropion	VERTEX PHARMACEUTICALS INC / MA (VRTX)
JZP441	Jazz Pharmaceuticals plc (JAZZ)
vx-433	VERTEX PHARMACEUTICALS INC / MA (VRTX)

Preclinical(1)

Drug	Company
CBS105	Harmony Biosciences Holdings, Inc. (HRMY)

Unknown(1)

Drug	Company
pitolisant GR	Harmony Biosciences Holdings, Inc. (HRMY)

Phase 2/Phase 3(3)

Drug	Company
Alixorexton (ALKS 2680)	Alkermes plc. (ALKS)
cleminorexton	Centessa Pharmaceuticals plc (CNTA)
tak-360	Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK)

Phase 4(2)

Drug	Company
JZP258	Jazz Pharmaceuticals plc (JAZZ)
Xywav	Jazz Pharmaceuticals plc (JAZZ)

BioSniper tracks 30 drugs in development for Narcolepsy across 14 companies.

There are 8 clinical trials targeting Narcolepsy tracked by BioSniper.

The estimated prevalence of Narcolepsy is approximately 30.0 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.